Treatment Outcomes with Lisdexamfetamine Dimesylate in Children Who Have Attention-Deficit/Hyperactivity Disorder with Emotional Control Impairments

被引:8
|
作者
Katic, Alain
Dirks, Bryan [1 ]
Babcock, Thomas [2 ]
Scheckner, Brian [2 ]
Adeyi, Ben [3 ]
Richards, Cynthia [1 ]
Findling, Robert L. [4 ]
机构
[1] Shire Dev LLC, Clin Dev & Innovat, Wayne, PA USA
[2] Shire Dev LLC, Global Med Affairs, Wayne, PA USA
[3] Shire Dev LLC, Biostat & Stat Programming Dept, Wayne, PA USA
[4] Johns Hopkins Univ, Johns Hopkins Med & Kennedy Krieger Inst, Div Child & Adolescent Psychiat, Baltimore, MD USA
关键词
DEFICIT HYPERACTIVITY; EXPRESSION;
D O I
10.1089/cap.2012.0104
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: The purpose of this study was to assess lisdexamfetamine dimesylate (LDX) treatment effects based on baseline emotional control dysfunction in children with attention-deficit/hyperactivity disorder (ADHD) categorized with or without impairments of executive function (EF) emotional control. Methods: Post-hoc analyses of a 7 week, open-label LDX study in children with ADHD (American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision [DSM-IV-TR] defined) and impairments in EF control of emotional response. At baseline, participants were dichotomized by Behavior Rating Inventory of EF (BRIEF) emotional control domain T-scores of >= 65 (with impairment) or <65 (without impairment). ADHD Rating Scale-IV (ADHD-RS-IV), BRIEF Global Executive Composite and emotional control domain, Expression and Emotion Scale for Children (EESC) scores, Pearson correlations for BRIEF versus ADHD-RS-IV and EESC, and Clinical Global Impressions scores were assessed at baseline and end of study (week 7)/early termination (EOS/ET) by baseline category of BRIEF emotional control impairment. Safety assessments included treatment-emergent adverse events (TEAEs). Results: At baseline and EOS/ET, respectively, 53.0% and 20.7% met criteria for emotional control impairment. Participants with and without emotional control impairments had similar ADHD-RS-IV change scores. Mean (SD) change from baseline for those with and without emotional control impairments were -20.8 (12.89) and -14.6 (11.25) for BRIEF global scores and -16.0 (13.19) and -5.0 (9.48) for BRIEF emotional control domain scores. Participants with emotional control impairments had greater mean EESC total score changes. BRIEF emotional control domain and all ADHD-RS-IV scores indicated moderate correlations between change scores (all p < 0.0001). Overall, 84.9% of participants had TEAEs (mostly mild-to-moderate in severity); 3.8% discontinued because of TEAEs. Conclusions: The proportion of children with behavioral impairments in EF control of emotional response decreased during LDX treatment. ADHD symptoms improved in both groups. The moderate correlations between EF behaviors and ADHD symptoms suggest there may be utility in evaluating behavioral domains beyond core ADHD symptoms.
引用
收藏
页码:386 / 393
页数:8
相关论文
共 50 条
  • [21] Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe
    Siffel, Csaba
    Page, Matthew
    Maxwell, Tricia
    Thun, Barbara
    Kolb, Nikolaus
    Rosenlund, Mats
    von Bredow, Dorothea
    Keja, Jacco
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2020, 30 (07) : 439 - 447
  • [22] Clinical Response and Symptomatic Remission in Children Treated With Lisdexamfetamine Dimesylate for Attention-Deficit/Hyperactivity Disorder
    Findling, Robert L.
    Adeyi, Ben
    Chen, Gary
    Dirks, Bryan
    Babcock, Thomas
    Scheckner, Brian
    Lasser, Robert
    Pucci, Michael L.
    Abdullah, Huda I.
    McGough, James J.
    CNS SPECTRUMS, 2010, 15 (09) : 559 - 568
  • [23] Efficacy and Safety of Lisdexamfetamine Dimesylate in Children with Attention-Deficit/Hyperactivity Disorder and Recent Methylphenidate Use
    Jain, Rakesh
    Babcock, Thomas
    Burtea, Teodor
    Dirks, Bryan
    Adeyi, Ben
    Scheckner, Brian
    Lasser, Robert
    Renna, John
    Duncan, Don
    ADVANCES IN THERAPY, 2013, 30 (05) : 472 - 486
  • [24] Lisdexamfetamine in the treatment of attention-deficit/hyperactivity disorder in adults
    Anthony L. Rostain
    Current Psychiatry Reports, 2009, 11 : 341 - 342
  • [25] Lisdexamfetamine in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults
    Rostain, Anthony L.
    CURRENT PSYCHIATRY REPORTS, 2009, 11 (05) : 341 - 342
  • [26] Lisdexamfetamine: A prodrug for the treatment of attention-deficit/hyperactivity disorder
    Popovic, Biljana
    Brattacharya, Pratik
    Sivaswamy, Lalitha
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (22) : 2005 - 2012
  • [27] Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity
    Ginsberg, Lawrence
    Katic, Alain
    Adeyi, Ben
    Dirks, Bryan
    Babcock, Thomas
    Lasser, Robert
    Scheckner, Brian
    Adler, Lenard A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (06) : 1097 - 1107
  • [28] Safety outcomes from the clinical development programme for lisdexamfetamine dimesylate: a prodrug stimulant for the treatment of attention-deficit/hyperactivity disorder
    Coghill, David
    Sorooshian, Shaw
    Caballero, Beatriz
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2013, 22 : S224 - S224
  • [29] European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder
    Coghill, David
    Banaschewski, Tobias
    Lecendreux, Michel
    Soutullo, Cesar
    Johnson, Mats
    Zuddas, Alessandro
    Anderson, Colleen
    Civil, Richard
    Higgins, Nicholas
    Lyne, Andrew
    Squires, Liza
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 (10) : 1208 - 1218
  • [30] Long-term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention-deficit/hyperactivity disorder
    Ichikawa, Hironobu
    Miyajima, Tasuku
    Yamashita, Yushiro
    Fujiwara, Masakazu
    Fukushi, Akimasa
    Saito, Kazuhiko
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2020, 40 (01) : 52 - 62